Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 14/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14794600 | 0.94 | CHRM4 (0.45) | CHRM4SMN1; SMN2IRAK4MAPK1KDM4E | |
| SCHEMBL14794648 | 0.88 | CHRM4 (0.54) | CHRM4SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL16273199 | 0.87 | CHRM4 (0.53) | CHRM4SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL14794153 | 0.86 | CHRM4 (0.45) | CHRM4IRAK4MAPK1ADORA3ADORA2A | |
| SCHEMBL14794375 | 0.86 | CHRM4 (0.45) | CHRM4SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL14794619 | 0.84 | CHRM4 (0.42) | CHRM4SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL14794447 | 0.83 | CHRM4 (0.45) | CHRM4SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL16273217 | 0.81 | CHRM4 (0.39) | CHRM4SMN1; SMN2IRAK4MAPK1KDM4E | |
| SCHEMBL14794626 | 0.80 | CHRM4 (0.49) | CHRM4MAPK1KDM4EALDH1A1 | |
| SCHEMBL16273188 | 0.78 | SMN1; SMN2 (0.43) | CHRM4SMN1; SMN2MAPK1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056876-B2 | Substituted 1H-pyrazolo[3′,4′,4,5]thieno[2,3-b]pyridin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2015-06-16 | — | — | US | claimed |
| US-9056876-B2 | Substituted 1H-pyrazolo[3′,4′,4,5]thieno[2,3-b]pyridin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056876-B2 | Substituted 1H-pyrazolo[3′,4′,4,5]thieno[2,3-b]pyridin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056876-B2 | Substituted 1H-pyrazolo[3′,4′,4,5]thieno[2,3-b]pyridin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2015-06-16 | — | — | US | disclosed |
| US-20140357615-A1 | SUBSTITUTED 1H-PYRAZOLO[3',4',4,5]THIENO[2,3-B]PYRIDIN-3-AMINE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2014-12-04 | — | — | US | disclosed |
| US-20140357615-A1 | SUBSTITUTED 1H-PYRAZOLO[3',4',4,5]THIENO[2,3-B]PYRIDIN-3-AMINE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2014-12-04 | — | — | US | disclosed |
| US-20140357615-A1 | SUBSTITUTED 1H-PYRAZOLO[3',4',4,5]THIENO[2,3-B]PYRIDIN-3-AMINE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2014-12-04 | — | — | US | disclosed |
| WO-2013040534-A1 | SUBSTITUTED 1H-PYRAZOLO[3',4',4,5]THIENO[2,3-B]PYRIDIN-3-AMINE ANALOGS AS POSITIVE ALLOSTERIC MODULATIORS OF THE MUSCARINIC ACETYCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357615-A1 | SUBSTITUTED 1H-PYRAZOLO[3',4',4,5]THIENO[2,3-B]PYRIDIN-3-AMINE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYCHOLINE RECEPTOR M4 | CHRM4, CHRM3, CHRM5 | CHRM4 1/4885SMN1; SMN2 2860/4885IRAK4 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.